Display options
Cite
Lacroix C, Bera-Jonville AP, Montastruc F, et al. Serious Neurological Adverse Events of Ceftriaxone. Antibiotics (Basel). 2021;10(5)doi: 10.3390/antibiotics10050540.
Lacroix, C., Bera-Jonville, A. P., Montastruc, F., Velly, L., Micallef, J., & Guilhaumou, R. (2021). Serious Neurological Adverse Events of Ceftriaxone. Antibiotics (Basel, Switzerland), 10(5), . https://doi.org/10.3390/antibiotics10050540
Lacroix, Clémence, et al. "Serious Neurological Adverse Events of Ceftriaxone." Antibiotics (Basel, Switzerland) vol. 10,5 (2021). doi: https://doi.org/10.3390/antibiotics10050540
Lacroix C, Bera-Jonville AP, Montastruc F, Velly L, Micallef J, Guilhaumou R. Serious Neurological Adverse Events of Ceftriaxone. Antibiotics (Basel). 2021 May 06;10(5). doi: 10.3390/antibiotics10050540. PMID: 34066591; PMCID: PMC8148437.
Copy Download .nbib Format: NLM
Share it on

Antibiotics (Basel). 2021 May 06;10(5). doi: 10.3390/antibiotics10050540.

Serious Neurological Adverse Events of Ceftriaxone.

Antibiotics (Basel, Switzerland)

Clémence Lacroix, Annie-Pierre Bera-Jonville, François Montastruc, Lionel Velly, Joëlle Micallef, Romain Guilhaumou

Affiliations

  1. Centre Régional de Pharmacovigilance, Service de Pharmacologie Clinique, APHM, INSERM, Institut Neurosciences Système, UMR 1106, Aix Marseille Université, 13005 Marseille, France.
  2. Centre Régional de Pharmacovigilance et d'Information sur le Médicament Centre-Val-de-Loire, Service de Pharmacosurveillance, Centre Hospitalier Régional Universitaire de Tours, 37000 Tours, France.
  3. Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Faculté de Médecine, 31000 Toulouse, France.
  4. Unité Clinique de Pharmacologie Psychiatrique, Faculté de Médecine, Centre Hospitalier Universitaire, 31000 Toulouse, France.
  5. Department of Anaesthesiology and Critical Care Medicine, University Hospital Timone, Aix Marseille Université, 13005 Marseille, France.
  6. CNRS, INT, Institut Neurosci Timone, UMR 7289, Aix Marseille Université, 13005 Marseille, France.
  7. Laboratoire de Pharmacologie Clinique, Service de Pharmacologie Clinique, APHM, INSERM, Institut Neurosciences Système, UMR 1106, Aix Marseille Université, 13005 Marseille, France.

PMID: 34066591 PMCID: PMC8148437 DOI: 10.3390/antibiotics10050540

Abstract

We described ceftriaxone-induced CNS adverse events through the largest case series of Adverse Drug Reactions (ADRs) reports, from 1995 to 2017, using the French Pharmacovigilance Database. In total, 152 cases of serious CNS ADRs were analyzed; 112 patients were hospitalized or had a prolonged hospitalization (73.7%), 12 dead (7.9%) and 16 exhibited life-threatening ADRs (10.5%). The median age was 74.5 years, mainly women (55.3%), with a median creatinine clearance of 35 mL/min. Patients mainly exhibited convulsions, status epilepticus, myoclonia (

Keywords: adverse effects; antibiotics; ceftriaxone; central nervous system; neurologic; neurotoxicity; pharmacovigilance

References

  1. Intern Med. 2019 Jun 15;58(12):1775-1779 - PubMed
  2. Clin Ther. 2014 Nov 1;36(11):1489-1511.e4 - PubMed
  3. Neth J Med. 2009 Feb;67(2):72-5 - PubMed
  4. Antibiotics (Basel). 2019 Jun 12;8(2): - PubMed
  5. Alcohol Alcohol. 2011 May-Jun;46(3):239-46 - PubMed
  6. J Clin Neurosci. 2019 Sep;67:163-166 - PubMed
  7. J Neurol Sci. 2019 Mar 15;398:196-201 - PubMed
  8. Therapie. 2013 Mar-Apr;68(2):69-76 - PubMed
  9. Intern Med. 2017 Nov 15;56(22):3103-3107 - PubMed
  10. Clin Pharmacokinet. 2000 Mar;38(3):271-90 - PubMed
  11. J Antimicrob Chemother. 2001 Apr;47(4):421-9 - PubMed
  12. Epilepsia. 2005 Sep;46(9):1550-2 - PubMed
  13. Antibiotics (Basel). 2021 Feb 10;10(2): - PubMed
  14. Neurology. 2016 Mar 8;86(10):963-71 - PubMed
  15. Neuroscience. 2016 Jun 21;326:117-125 - PubMed
  16. Eur J Clin Microbiol Infect Dis. 2005 Oct;24(10):649-53 - PubMed
  17. Clin Pharmacokinet. 1989 Oct;17(4):223-35 - PubMed
  18. J Antimicrob Chemother. 2019 Apr 1;74(4):1078-1085 - PubMed
  19. Antimicrob Agents Chemother. 1981 Nov;20(5):634-41 - PubMed
  20. Neurosci Lett. 2012 Feb 16;509(2):69-71 - PubMed
  21. Joint Bone Spine. 2006 Dec;73(6):629-32 - PubMed
  22. J Antimicrob Chemother. 2018 Jun 1;73(6):1620-1629 - PubMed
  23. Kidney Int Rep. 2017 Apr 07;2(5):984-987 - PubMed
  24. Ann Pharmacother. 2008 Dec;42(12):1843-50 - PubMed
  25. Antibiotics (Basel). 2018 Dec 22;8(1): - PubMed
  26. Antimicrob Agents Chemother. 2019 Feb 26;63(3): - PubMed
  27. Postgrad Med J. 2018 Jun;94(1112):357-358 - PubMed
  28. Clin Pharmacokinet. 1998 Jul;35(1):49-64 - PubMed
  29. Case Rep Nephrol. 2014;2014:108185 - PubMed
  30. Epilepsy Behav Case Rep. 2016 May 20;6:23-7 - PubMed
  31. Antibiotics (Basel). 2021 Mar 25;10(4): - PubMed
  32. Indian J Pharmacol. 2012 Jan;44(1):124-5 - PubMed
  33. Crit Care. 2019 Mar 29;23(1):104 - PubMed
  34. Br J Clin Pharmacol. 2015 Sep;80(3):525-33 - PubMed
  35. Br J Clin Pharmacol. 2011 Nov;72(5):758-67 - PubMed
  36. JAMA Intern Med. 2017 Sep 1;177(9):1308-1315 - PubMed
  37. Arq Neuropsiquiatr. 2014 Aug;72(8):643-4 - PubMed
  38. Pediatr Neurol. 2004 Feb;30(2):135-9 - PubMed
  39. Br J Clin Pharmacol. 2011 Sep;72(3):381-93 - PubMed
  40. Biol Psychiatry. 2010 Jan 1;67(1):81-4 - PubMed
  41. Am J Med Sci. 2010 Nov;340(5):382-4 - PubMed
  42. Int J Antimicrob Agents. 2004 Mar;23(3):213-7 - PubMed
  43. Antimicrob Agents Chemother. 2019 Aug 23;63(9): - PubMed
  44. Neurology. 2015 Oct 13;85(15):1332-41 - PubMed
  45. Lancet. 2011 Jul 16;378(9787):288 - PubMed
  46. J Korean Med Sci. 2012 Sep;27(9):1120-3 - PubMed
  47. Drug Saf. 2017 Dec;40(12):1171-1198 - PubMed
  48. Am J Med. 2001 Aug;111(2):115-9 - PubMed

Publication Types